Skip to main content
Fig. 5 | Molecular Brain

Fig. 5

From: Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation

Fig. 5

Effect of everolimus treatment on seizure and general behavioral features. a The median seizure frequency and duration decreased compared to that prior to everolimus treatment. EEG showed run of spikes in the right fronto-polar region prior to everolimus treatment (left side), whereas no epileptiform discharge was observed following treatment (right side). b In the evaluation of the improvement in general and autistic behavioral features, ATEC showed a decrease in the scores in all four categories (Speech/Language/Communication, Sociability, Sensory/Cognitive awareness, and Health/Physical/Behavior) after everolimus treatment compared to pre-treatment

Back to article page

Molecular Brain

ISSN: 1756-6606